Augmentation and combination strategies in treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 18, 2001, Pages 4-11

  Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,11 METHENYLTETRAHYDROHOMOFOLIC ACID; 5,11-METHENYLTETRAHYDROHOMOFOLATE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; FOLIC ACID; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PRASTERONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEHYDROEPIANDROSTERONE; DEPRESSIVE DISORDER; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FOLIC ACID; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0035233551     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
2. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225
3. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;42:281-290
4. Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry 1999;6:322-326
5. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000;61:403-108
6. Joffe RT, Levitt AJ. Relationship between antidepressant partial and nonresponse and subsequent response to antidepressant augmentation. J Affect Disord 1999;52:257-259
7. Johnson FN. Lithium augmentation therapy. Rev Contemp Pharmacother 1991;2:1-52
8. Price LH. Pharmacological strategies in refractory depression. In: Tasman A, Goldfinger SM, Kaufman CA, eds. American Psychiatric Press Review of Psychiatry, vol 9. Washington, DC: American Psychiatric Press; 1990:116-131
9. Himmelhoch JM, Detre T, Kupfer DJ, et al. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis 1972;155:216-220
10. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 1985;142:619-623
11. Fein S, Paz V, Rao N, et al. The combination of lithium carbonate and an MAOI in refractory depressions. Am J Psychiatry 1988;145:249-250
12. Dinan TG. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 1993;88:300-301
13. Baumann P, Souche A, Montaldi S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996;16:307-314
14. Cournoyer G, De Montigny C, Oulette J, et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. Presented at the Congress Internationale Neuro-Psychopharmacologicum meeting; June 9-23, 1984; Florence, Italy
15. Fava M, Rosenbaum J, McGrath P, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression. Am J Psychiatry 1994;15:1372-1374
16. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant action: an effective prescription for treatment refractory depression. Arch Gen Psychiatry 1983;40:1335-1342
17. Joffe RT, Singer W, Levitt AJ, et al. A placebo controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
18. Kantor D, McNeven S, Leichner P, et al. The benefit of lithium carbonate adjunct in refractory depression: fact or fiction? Can J Psychiatry 1986;31:416-418
19. Katona, CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995;166:80-86
20. Schopf J, Baumann P, Lemarchand T, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Pharmacopsychiatry 1989;22:183-187
21. Stein G, Bernadt M. Double-blind trial of lithium carbonate in tricyclic resistant depression. In: Birch NJ, ed. Lithium: Inorganic Pharmacology and Psychiatric Use. Oxford, UK: IRL Press; 1988:35-36
22. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993;162:634-640
23. Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988;8:120-124
24. de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 1983;40:1327-1334
25. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate [letter]. Am J Psychiatry 1989;146:278
26. Prange AJ Jr. Novel uses of thyroid hormones in patients with affective disorders. Thyroid 1996;6:537-543
27. Aronson R, Offman HJ, Joffe T, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996;53:842-848
28. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
29. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-271
30. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. South Afr Med J 1997;87(4, suppl):534-537, 540
31. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998;18:465-469
32. Fischer P, Tauscher J, Kufferle B, et al. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol 1998;13:83-86
33. Landén M, Björling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59:664-668
34. Landén M, Eriksson E, Agren H, et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999;19:268-271
35. Perez V, Gilaberte I, Faries D, et al. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597
36. Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotoninergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-89
37. Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997;17:446-450
38. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155:1346-1351
39. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):16-23; discussion 24-25